Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma

被引：0
|
作者：
Samples, Laura S.
Sadrzadeh, Hossein
Frigault, Matthew J.
Jacobson, Caron Alyce
Hamadani, Mehdi
Gurumurthi, Ashwath
Strati, Paolo
Shouval, Roni
Riedell, Peter A.
Dahiya, Saurabh
Yared, Jean
Jain, Michael D.
Locke, Frederick L.
Leslie, Lori Ann
Epperla, Narendranath
Ghosh, Monalisa
Skarbnik, Alan
Hill, Brian T.
Kamdar, Manali K.
Shadman, Mazyar
机构：
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA USA
[2] Boston Univ, Med Ctr, Boston, MA USA
[3] Massachusetts Gen Hosp, Boston, MA USA
[4] Dana Farber Canc Inst, Boston, MA USA
[5] Med Coll Wisconsin, Milwaukee, WI USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[8] Mem Sloan Kettering Canc Ctr, New York, NY USA
[9] Univ Chicago, Med Ctr, Chicago, IL USA
[10] Stanford Canc Ctr GI Surg Oncol, Stanford, CA USA
[11] Univ Maryland, Baltimore, MD USA
[12] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[13] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[14] John Theurer Canc Ctr, Hackensack, NJ USA
[15] Ohio State Univ, Columbus, OH USA
[16] Univ Michigan, Hlth Management Res Ctr, Ann Arbor, MI USA
[17] Novant Hlth Canc Inst, Charlotte, NC USA
[18] Cleveland Clin, Cleveland, OH USA
[19] Univ Colorado Hosp, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7571
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Aggressive Lymphoma after CD19 CAR T-Cell Therapy
    Kobbe, Guido
    Bruggemann, Monika
    Baermann, Ben-Niklas
    Wiegand, Laura
    Trautmann, Heiko
    Yousefian, Schayan
    Libertini, Silvana
    Menssen, Hans D.
    Maier, Harald J.
    Ulrich, Peter
    Gao, Jingbo
    Bruch, Peter-Martin
    Liebers, Nora
    Radujkovic, Aleksandar
    Seifert, Marc
    Schniederjohann, Christina
    Paramasivam, Nagarajan
    Fitzgerald, Donnacha
    Seidel, Maximilian
    Esposito, Irene
    Germing, Ulrich
    Cadeddu, Ron-Patrick
    Nachtkamp, Kathrin
    Jaeger, Paul
    Ulrych, Thomas
    Fischer, Johannes C.
    Rox, Jutta M.
    Giesel, Frederik
    Koch, Raphael
    Antoch, Gerald
    Distler, Joerg H. W.
    Meuth, Sven G.
    Jacobsen, Malte
    Hubschmann, Daniel
    Lu, Junyan
    Iaccarino, Ingram
    Haas, Simon
    Damm, Frederik
    Dietrich, Sascha
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (13): : 1217 - 1226
  • [2] Feasibility of CD19 CAR T-cell therapy in patients with cardiac lymphoma
    Kuipers, Maria T.
    Spanjaart, Anne M.
    Bonifazi, Francesca
    diBlasi, Roberta
    Zinzani, Pier L.
    Thieblemont, Catherine
    Baudet, Mathilde
    Biemond, Bart J.
    Kok, Wouter E. M.
    Kersten, Marie J.
    LEUKEMIA & LYMPHOMA, 2024, 65 (03) : 399 - 402
  • [3] Paving the road ahead for CD19 CAR T-cell therapy
    Nellan, Anandani
    Lee, Daniel W.
    CURRENT OPINION IN HEMATOLOGY, 2015, 22 (06) : 516 - 520
  • [4] Secondary malignancy after CD19 CAR T-cell therapy
    Rudek, Loreen Sophie
    Alakus, Hakan
    ONKOLOGIE, 2025,
  • [5] Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with CD19 CAR T-cell lymphoma therapy
    Nie, Esther
    Ahmadian, Saman
    Bharadwaj, Sushma
    Acosta-Alvarez, Lehi
    Threlkeld, Zachary
    Frank, Matthew
    Miklos, David
    Born, Donald
    Scott, Brian
    Monje, Michelle
    Vogel, Hannes
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2022, 81 (06): : 464 - 464
  • [6] Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
    Wudhikarn, Kitsada
    Tomas, Ana Alarcon
    Flynn, Jessica R.
    Devlin, Sean M.
    Brower, Jamie
    Bachanova, Veronika
    Nastoupil, Loretta J.
    McGuirk, Joseph P.
    Maziarz, Richard T.
    Oluwole, Olalekan O.
    Schuster, Stephen J.
    Porter, David L.
    Bishop, Michael R.
    Riedell, Peter A.
    Perales, Miguel-Angel
    Cell Therapy Consortium
    BLOOD ADVANCES, 2023, 7 (13) : 3192 - 3198
  • [7] Therapies and outcomes following extramedullary relapse of pediatric and young adult ALL after CD19 CAR T-cell therapy
    Friedes, Barbara D.
    Dino, Amanda M.
    Iannone, Emma
    Li, Yimei
    Rheingold, Susan R.
    Leahy, Allison Barz
    Wray, Lisa
    Callahan, Colleen
    Baniewicz, Diane
    Vernau, Lauren
    Getz, Kelly D.
    Aplenc, Richard
    Maude, Shannon L.
    Grupp, Stephan A.
    Myers, Regina M.
    BLOOD ADVANCES, 2025, 9 (02) : 354 - 359
  • [8] OUTCOMES OF COMMERCIAL AND IN-HOUSE ANTI CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY B-CELL LYMPHOMA IN SINGAPORE
    Ong, Shin Yeu
    Krisnadi, Cindy
    Wang, Samuel Sherng Young
    Chen, Yun Xin
    Seng, Michaela Su-fern
    Soh, Shui Yen
    Chan, Esther Hian Li
    Hwang, William Ying Khee
    Ho, Aloysius Yew Leng
    Lim, Francesca Lorraine Wei Inng
    BONE MARROW TRANSPLANTATION, 2024, 59 : 226 - 226
  • [9] CD19 CAR-T cell treatment of CNS relapse of Burkitt's lymphoma: A case report
    Baur, R.
    Aigner, M.
    Voelkl, S.
    Jacobs, B.
    Gary, R.
    Kretschmann, S.
    Achenbach, S.
    Mackensen, A.
    Mougiakakos, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 242 - 242
  • [10] CAR19/22 T cell therapy in adult refractory Burkitt’s lymphoma
    Xiaoxi Zhou
    Tong Ge
    Tongjuan Li
    Liang Huang
    Yang Cao
    Yi Xiao
    Miao Zhen
    Liting Chen
    Jianfeng Zhou
    Cancer Immunology, Immunotherapy, 2021, 70 : 2379 - 2384
12345